Mary Caffrey

Managing the constantly evolving selection of therapies in oncology can be difficult, but is of the utmost importance to get the right treatment to the right patient, agreed a panel at Patient-Centered Oncology Care® 2020.

At the recent meeting of the American Society of Hematology, results from several studies involved the use of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

According to the final panel at Patient-Centered Oncology Care®, clinical pathways can create a new problem: if each payer tries to impose its own pathways, it’s an administrative and ethical nightmare.

In an interview with Evidence-Based Oncology™, City of Hope's Harlan Levine discussed the rising interest of employers in cancer care and how AccessHope can help them deliver better care where their employees live.

The keynote address at Patient-Centered Oncology Care® 2020 focused on the way practices have benefitted from the Oncology Care Model as the pandemic wears on.

A panel at Patient-Centered Oncology Care® 2020 discussed the challenges of a pandemic as oncology practice transformation initiatives continue on.

The panel could not reach consensus on what an expanded label might look like in an area where there are no approved therapies.

Barbara McAneny, MD, CEO of New Mexico Oncology Hematology Consultants, discusses the issues with placing risk on oncologists as they work to provide quality care to patients.

Karl Kilgore, PhD, a senior research scientist at Avalere Health, discusses Medicare data that offer insights on the overall costs of CAR T-cell therapy relative to transplants.

A late-breaking study presented at the American Society of Hematology annual meeting raises the specter of whether interventions can occur decades before a blood cancer would appear.

The treatment appeared to live up to its billing of having fewer off-target effects in studies presented at the American Society of Hematology.

Doctors who treated patients with sickle cell disease who received an infusion of gene-edited treatment have called it "transformative" for those who live with a chronic condition.

Three researchers presented results on COVID-19 therapies and data of importance to patients with hematological conditions.

Researchers from the University of California San Francisco published their results in the Journal of Urology.

Results were released for a leading chimeric antigen receptor (CAR) T-cell therapy candidate in multiple myeloma, along with long-term findings for an early treatment that may soon face competition.

The lead investigator touted the benefits of subcutaneous administration of daratumumab in relapsed multiple myeloma (MM) during a presentation on practice-changing results ahead of the American Society of Hematology annual meeting.

A preview of the 62nd annual American Society of Hematology meeting, taking place in a virtual format.

Penn Medicine researchers use mice experiments to find a potential solution to the challenge of delivering CAR T cell treatments to solid tumors in glioblastoma.

City of Hope's Dr. Tanya Siddiqi offers an update on a new chimeric antigen receptor (CAR) T-cell therapy awaiting approval from the FDA.

Authors in the Journal of Clinical Oncology discuss hypotheses on the differences in mutations and implications for treatment with PARP inhibitors.

Dr. Anthony Fauci discusses the cardiovascular implications of coronavirus disease 2019 (COVID-19) at the American Heart Association Scientific Sessions.

After recent setbacks, the beleaguered drug reduced cardiovascular events and may be a choice for patients with severe chronic kidney disease.

The investigator of the STRENGTH study says findings raise questions about the landmark REDUCE-IT trial, but other evidence suggests the drugs involved are different.

A registry study suggests 4 in 5 patients with heart failure might benefit from the SGLT2 inhibitor dapagliflozin.

The vice president for Clinical Services at OneOncology describes challenges and opportunities for chimeric antigen receptor (CAR) T-cell therapy in the community practice setting.

An investigational drug, IMM-101, already being studied for its ability to increase the effects of immuno-oncology agents, may be able to prevent or lessen the effects of COVID-19 among those with cancer.

A discussion of the final Radiation Oncology Model; after this article went to press, CMS announced a delay until July 2021, reflecting concerns of radiation oncologists.

Value-based insurance design has made gains in oncology, but there's more work to do.

A look at the special challenges of delivering cancer care in rural areas, as ASCO seeks to address this issue.